# Chai Discovery raises $130M to scale Chai-2 and fast-track AI-designed antibodies

> Chai Discovery raised $130M to build a CAD-style suite for molecules and speed zero-shot antibody design. Reported 16% success on 52 targets, two-week loops, $1.3B valuation.

- Type: AI news
- Page: https://completeaitraining.com/news/chai-discovery-raises-130m-to-scale-chai-2-and-fast-track/
- Published: 2025-12-17
- Updated: 2026-02-18
- Author: Jeroen Erne
- Jobs: Product development
- Reading time: 3 min

### Chai's the Limit: $130M To Build a CAD Suite for Molecules

Chai Discovery just closed a **$130 million Series B** to speed up R&D and push commercialization of its AI platform for de novo antibody design. The company's ambition is clear: create the equivalent of a computer-aided design suite for molecules, where you specify properties upfront and generate candidates that fit.

With this round, Chai's total funding climbs above **$225 million** and the company is now valued at **$1.3 billion**. For product teams, the signal is strong: the spec-first, simulation-heavy model that software enjoys is moving into therapeutics-see [Design](https://completeaitraining.com/tag/design/).

#### What's new: zero-shot antibody design that ships

- **Chai-2** is a zero-shot generative platform producing de novo antibodies with **double-digit success rates**.
- Reported **16% success** across ≤20 molecules per target on **52 diverse targets**\-over **100x** better than prior computational methods. The design-to-wet-lab loop finished in **under two weeks** ([bioRxiv](https://www.biorxiv.org/?ref=completeaitraining.com)).
- Updated data: **>86% of full-length mAbs** show strong developability on par with therapeutic antibodies; resolved structures align with in silico predictions, indicating atomistic accuracy.
- Scale: initial benchmark on 50+ targets; internal testing now on **100+ targets**.

#### Why product teams should care

- **Spec-first development:** Define target class, affinity, specificity, and developability early. Generate candidates that meet those specs instead of endless tweak-and-test.
- **Shorter build-measure-learn loops:** From design to wet-lab validation in weeks, not quarters.
- **Higher-fidelity simulation:** Structural agreement between predictions and resolved designs raises confidence in pre-experiment decisions.
- **Small teams, big throughput:** Chai operates with ~**25 people**\-a hint at what lean, model-centric orgs can ship.

#### How they're building it

Chai is led by co-founders **Joshua Meier (CEO)**, **Matthew McPartlon**, **Jacques Boitreaud**, and **Jack Dent**. Meier's path runs through Harvard, OpenAI (GPT-1/2 era), Meta's generative biology group (co-led **ESM1**), and Absci (as chief AI officer) where McPartlon led de novo antibody modeling. Boitreaud previously scaled AI tools for small molecules at Aqemia; Dent built product and engineering teams at Stripe.

As Meier puts it, "If these models can understand natural language, why can't they understand DNA and proteins?" The bet: language-model scale and training methods translate to biology-and hit an inflection point for drug discovery.

#### Funding and market signal

The round was co-led by **Oak HC/FT** and **General Catalyst**. Participants include **Thrive Capital**, **OpenAI**, **Dimension**, **Menlo Ventures**, **Lachy Groom**, **Yosemite**, **Neo**, **SV Angel**, with new investors **Emerson Collective** and **Glade Brook Capital Partners**. Chai also added **Mikael Dolsten, MD, PhD** (former Pfizer CSO) to its board, plus **Annie Lamont** (Oak HC/FT) and **Hemant Taneja** (General Catalyst).

Context: VC funding in AI drug development hit **$2.7B** through the first three quarters of 2025, and AI-native biotechs see a near **100% valuation premium** over conventional peers ([PitchBook](https://pitchbook.com/?ref=completeaitraining.com)).

#### Product implications: what to do next

- **Define the spec sheet early:** Target, epitope strategy, affinity thresholds, developability, manufacturability, and safety flags. Treat it like a product PRD.
- **Instrument the loop:** Automate wet-lab queues, data capture, and feedback into model training. Latency and throughput are now product levers.
- **Evaluate models with real KPIs:** Success rate per target class, diversity of hits, off-target risk, developability metrics, and time-to-validation.
- **Build vs. partner:** If you lack high-quality assay data or ML infra, partner first. Own your data flywheel as you scale.
- **Governance:** Put in model risk, audit trails, and versioning-follow [MCP](https://completeaitraining.com/tag/mcp-model-context-protocol/). Designs will become regulated artifacts.
- **Team design:** Cross-functional pods: ML, protein engineering, automation, and product ops. Keep the team small, shipping weekly.

#### Risks to track

- **False confidence:** Good in silico fit doesn't guarantee in vivo success; keep orthogonal assays in the loop.
- **Throughput mismatch:** Model speed outpacing wet-lab capacity creates bottlenecks-plan capacity and prioritization.
- **IP and data security:** Training data provenance and design ownership need clear policies.
- **Regulatory readiness:** Traceability from prompt to protein is essential for filings.

#### What to watch over the next year

- Therapeutic full-length mAb case studies entering later-stage validation.
- Performance on harder target classes and combination modalities.
- Adoption inside large biopharma pipelines; APIs that plug into existing ELN/LIMS and automation stacks.

#### Why this matters

Chai's approach moves drug design closer to software: define specs, generate candidates, validate fast, and feed results back into the model. If that loop holds, discovery becomes a product engine, not a scavenger hunt.

If your team is skilling up on AI-native product workflows, explore role-based programs here: [Complete AI Training - Courses by Job](https://completeaitraining.com/courses-by-job/).

---

This is the Markdown form of https://completeaitraining.com/news/chai-discovery-raises-130m-to-scale-chai-2-and-fast-track/. The whole site is mapped at https://completeaitraining.com/llms.txt.
